drugset / Trial / NCT07602257

Investigating a Personalized Approach to Anti-Platelet Therapy

NCT07602257

Phase 4 Not yet recruiting 1760 enrolled Ottawa Heart Institute Research Corporation
RandomizedSequentialSingle-blindPrevention

Summary

RAPID PREVENT aims to identify if a personalized (targeted) anti-platelet strategy will reduce bleeding events when compared to the current standard anti-platelet therapy.

Timeline

Start
2026-06-01
Primary completion
2029-12-28
Completion
2029-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule
Subject Clopidogrel Small molecule
Subject Ticagrelor Small molecule

Indications

No indication recorded.